Search clinical trials for: Rebif

Total 102 results

Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
German University in Cairo

Recruiting

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Multiple Sclerosis

Egypt
The Cleveland Clinic
University of Nottingham

Recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Spain, Czechia, Belgium, Italy, Canada, United Kingdom, Germany, Ireland, Turkey, Poland, Russian Federation, Ukraine, Croatia, Argentina, France, Belarus, Brazil, Mexico, Bosnia and Herzegovina, Bulgaria, Slovakia, S... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Rennes University Hospital

Completed

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis (MITOX-REBIF)

Multiple Sclerosis

France
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Merck KGaA, Darmstadt, Germany
Merck Serono Middle East FZ LLC

Completed

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS)

Bulgaria, Poland, Argentina, Hungary, Korea, Republic of, Saudi Arabia, Egypt, Algeria, Bahrain, Iran, Islamic Republic of, Kuwait, Lebanon, Morocco
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen
AMS Advanced Medical Services GmbH

Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (PERFECT)

Multiple Sclerosis, Relapsing-Remitting

Germany
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

Multiple Sclerosis

Italy
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands

Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (MESTRE-MS)

Multiple Sclerosis

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (RELIEF)

Multiple Sclerosis, Relapsing-Remitting

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Relapsing-Remitting Multiple Sclerosis

United States
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Merck KGaA, Darmstadt, Germany
Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany

Completed

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)

Clinically Isolated Syndrome | Relapsing Multiple Sclerosis

Germany
IMS HEALTH GmbH & Co. OHG
EMD Serono

Completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® (PROTRACT)

Relapsing-remitting Multiple Sclerosis

United States, Canada
EMD Serono

Completed

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
Merck KGaA, Darmstadt, Germany

Completed

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device (RebiQoL)

Multiple Sclerosis | Relapsing-Remitting

Sweden, Germany
Centre hospitalier de l'Université de Montréal...
EMD Serono Canada Inc.

Completed

Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif (RLO)

Multiple Sclerosis

Canada
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)

Multiple Sclerosis, Relapsing-Remitting

Australia, Denmark, Canada, United States, Netherlands, Argentina, Austria, Belgium, Brazil, Croatia, Czech Republic, France, Germany, Israel, Italy, Mexico, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine, United Kingdom
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
EMD Serono

Completed

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

Multiple Sclerosis, Relapsing-Remitting

United States
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Sanofi

Completed

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis (TENERE)

Multiple Sclerosis

Hungary, Belgium, Germany, Italy, Greece, France, Poland, Spain, Canada, Switzerland, Czech Republic, Tunisia, United Kingdom
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Healthy

Russian Federation
Merck KGaA, Darmstadt, Germany

Terminated

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) (ADHERQOL)

Multiple Sclerosis, Relapsing-remitting

Germany
Brigham and Women's Hospital
EMD Serono

Withdrawn

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Multiple Sclerosis

United States
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
Centre Hospitalier Universitaire Vaudois
BioPartners GmbH

Completed

Phase I BP Interferon (IFN) Beta-004

Multiple Sclerosis, Relapsing-Remitting
EMD Serono
Pfizer

Completed

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (RNF)

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)

Relapsing Remitting Multiple Sclerosis

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Relapsing Multiple Sclerosis

United Kingdom
EMD Serono

Completed

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (REPLAY)

Multiple Sclerosis

Italy, Russian Federation, United States, Argentina, Venezuela, Canada, Tunisia, France
EMD Serono

Terminated

Adherence Trial With MS LifeLines ® Services

Multiple Sclerosis | Relapsing-Remitting

United States
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Genzyme, a Sanofi Company
Bayer

Completed

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Russian Federation, Poland, Croatia, United Kingdom
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)

Multiple Sclerosis, Relapsing-Remitting

Australia, France, United States, Germany, Canada, United Kingdom, Russian Federation, Argentina, Brazil, Croatia, Poland, Serbia, Sweden, Ukraine, Czech Republic, Mexico
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France

Search clinical trials for: Rebif

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations